Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Custom Designed Microarrays Give Genomics Researchers Greater Flexibility

By LabMedica International staff writers
Posted on 02 Jun 2011
Genomics researchers can now order custom designed microarray plates that will allow them to evaluate samples with from 1,500 to 2.6 million markers.

The new Axiom myDesign Targeted Genotyping (TG) Arrays are a product of Affymetrix, Inc. More...
(Santa Clara, CA, USA). While Affymetrix encourages investigators to submit markers, many will prefer to depend on the well-characterized markers available in the Axiom Genomic Data Base.

The Axiom Genomic Database, with 11 million rare and common variants with minor allele frequency (MAF) greater than 1%, is derived from sources such as NHGRI, the International HapMap, and 1000 Genomes Project. Each marker is annotated by MAF, linkage disequilibrium (LD), and haplotype information, as well as SNP (single nucleotide polymorphism) classification and biological function. The database also contains approximately four million SNPs associated with key processes or pathways important to the study of pharmacogenomics genes, cardiovascular disease, the human leukocyte antigen (HLA) region, and inflammatory and immunity disease, as well as genes from the Sanger Cancer Gene Census and previous association studies.

Affymetrix has rendered the custom design process much simpler by creating the Axiom Design Center, an easy-to-use, web-based tool in that enables the researcher to quickly select markers from the Axiom Genomic Database and design the custom array. The Axiom Design Center provides access to markers based on gene symbol, chromosome, region, locus ID, biological category, or from previous commercial microarrays, including Affymetrix and others.

"Axiom myDesign TG Arrays will help researchers to quickly evaluate interesting variants from their GWAS (genome wide association study), sequencing, and candidate gene initiatives without limiting the number of markers in their study," said Andy Last, Chief Commercial Officer of Affymetrix. "Customers who want to add newly discovered content after they complete the initial design can benefit from our new flexible content capability without switching platforms."

Related Links:

Affymetrix, Inc.




Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.